CSIMarket Company Name, Ticker, Industry, else..
 
Acorda Therapeutics Inc   (ACORQ)
 

Acorda Therapeutics Inc's Suppliers Performance

ACORQ's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
ACORQ Costs vs Sales of Suppliers Growth Acorda Therapeutics Inc recorded an increase in cost of sales by 14.63 % year on year, relative to one quarter ago cost of sales fell by -33.77 % in Q1.

• More on ACORQ Suppliers



Acorda Therapeutics Inc recorded increase in cost of sales by 14.63 % year on year, compare to one quarter ago cost of sales fell by -33.77 % in Q1.

• More on ACORQ Suppliers




Acorda Therapeutics Inc's Comment on Supply Chain


The company relies on third-party manufacturers for the production of commercial supplies of Ampyra and Inbrija. It depends on collaborators and distributors to commercialize Inbrija and Ampyra outside the United States. Following the termination of its collaboration agreement with Biogen, the company plans to establish additional collaborations and distribution arrangements to transition the commercialization of Fampyra. The company faces risks related to the complex and regulated manufacturing processes for pharmaceuticals, which may impact the commercial supply of Inbrija. Third-party payers may not provide reimbursement for Inbrija at acceptable rates or may impose restrictive prior authorization requirements that could limit or prevent prescriptions. The company faces competition from generic versions of Ampyra in the United States and a generic version of Fampyra in Germany. Biogen is identified as a supplier in company filings.

Acorda Therapeutics Inc's Comment on Supply Chain


The company relies on third-party manufacturers for the production of commercial supplies of Ampyra and Inbrija. It depends on collaborators and distributors to commercialize Inbrija and Ampyra outside the United States. Following the termination of its collaboration agreement with Biogen, the company plans to establish additional collaborations and distribution arrangements to transition the commercialization of Fampyra. The company faces risks related to the complex and regulated manufacturing processes for pharmaceuticals, which may impact the commercial supply of Inbrija. Third-party payers may not provide reimbursement for Inbrija at acceptable rates or may impose restrictive prior authorization requirements that could limit or prevent prescriptions. The company faces competition from generic versions of Ampyra in the United States and a generic version of Fampyra in Germany. Biogen is identified as a supplier in company filings.







ACORQ's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Acorda Therapeutics Inc 0.00 99.94 -62.49 102
SUBTOTAL 0.00 0.00 0.00 -


Sources: Acorda Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Acorda Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.